Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma Expect to commence Phase 1/2 clinical trial in China.
Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 19, 2023 Gracell Biotechnologies Inc. , a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly.
Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma and patient screening underway in Phase 1b portionExpect to commence. -Today at 07:16 am- MarketScreener